English
Zydus Lifesciences Q2 Results
- BSE: 532321
- NSE: ZYDUSLIFE
- ISIN: INE010B01027
- Sector: Biotechnology & Drugs
BSE
924.35
-7.10 (-0.76%)
-7.10 (-0.76%)Volume31.99 K
Updated: Mon 8 Dec, 2025 | 15:57:55
NSE
924.60-6.85 (-0.74%)
-6.85 (-0.74%)Volume6.32 L
Updated: Mon 8 Dec, 2025 | 15:53:23
Technical Trends
Long TermConsiders price movement over the last 6 months
Not Available
Short TermConsiders price movement over the last 1-2 weeks
Not Available
- Bearish
- Moderately Bearish
- Neutral
- Moderately Bullish
- Bullish
Insight: Trends unavailable at the moment.
Q2 Results Highlights
- Total Income₹6,123.20 Cr.(16.92%)
- Operating Profit₹1,265.60 Cr.(7.04%)
- Profit After Tax₹1,258.60 Cr.(38.17%)
- Operating Margin20.67%(-8.45%)
Note: Comparison is on YoY basis
Quarterly - Zydus Lifesciences Q2 Results
*All figures in crores except per share values
| Fiscal Period | Sep 25 | Jun 25 | QoQ Comp | Sep 24 | YoY Comp |
|---|---|---|---|---|---|
| Total Operating Expense | 4,857.60 | 4,780.40 | 1.61% | 4,054.60 | 19.80% |
| Depreciation/ Amortization | 301.90 | 238.10 | 26.80% | 233.60 | 29.24% |
| Operating Income | 1,265.60 | 1,793.30 | -29.43% | 1,182.40 | 7.04% |
| Net Income | 1,258.60 | 1,466.80 | -14.19% | 911.20 | 38.13% |
| Other Operating Expenses Total | 1,796.80 | 1,747.60 | 2.82% | 1,470.40 | 22.20% |
| Net Income Before Taxes | 1,687.40 | 1,920.60 | -12.14% | 1,270.90 | 32.77% |
| Total Revenue | 6,123.20 | 6,573.70 | -6.85% | 5,237.00 | 16.92% |
| Selling/ General/ Admin Expenses Total | 1,034.20 | 1,005.20 | 2.88% | 879.20 | 17.63% |
| Diluted Normalized EPS | 12.76 | 14.58 | -12.49% | 9.06 | 40.87% |
EQUITY QUICK LINKS
FROM MARKETS
Trending Stocks
✕
Wait for it…
Oops! Looks like you have exceeded the limit to bookmark the image. Remove some to bookmark this image.